Haleon, GB00BMX86B70

Haleon stock (GB00BMX86B70): Consumer healthcare leader navigates market dynamics

Published on 05/13/2026 at 15:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Haleon plc, the FTSE 100-listed consumer healthcare company spun off from GSK, continues to establish itself as a standalone player in over-the-counter wellness products across global markets.

Haleon, GB00BMX86B70, Illustration mit AI erstellt.
Haleon, GB00BMX86B70, Illustration mit AI erstellt.

Haleon plc operates as a pure-play consumer healthcare company following its separation from GlaxoSmithKline, focusing on over-the-counter health and wellness solutions across the United States, Europe, and international markets. The company manufactures and markets a portfolio of recognized consumer healthcare brands serving millions of customers worldwide.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

  • Name: Haleon plc
  • Sector/industry: Consumer Healthcare, Over-the-Counter (OTC) Health Products
  • Headquarters/country: United Kingdom
  • Core markets: United States, Europe, International
  • Key revenue drivers: OTC wellness brands, consumer healthcare products
  • Home exchange/listing venue: London Stock Exchange (FTSE 100)
  • Trading currency: GBP

Haleon plc: core business model

Haleon operates as a dedicated consumer healthcare company with a diversified portfolio of over-the-counter health and wellness products. The company serves consumers across multiple geographies through established brand recognition and distribution networks. As a former division of GlaxoSmithKline, Haleon inherited a strong foundation in consumer health innovation and market presence, positioning itself to compete independently in the global OTC healthcare sector.

Main revenue and product drivers for Haleon

The company generates revenue through its Consumer Self-Care Americas and Consumer Self-Care International segments, serving demand for accessible health and wellness solutions. Haleon's product portfolio spans pain relief, cold and flu remedies, digestive health, and other consumer wellness categories. The company benefits from secular trends toward self-care and preventive health management, particularly in developed markets where OTC healthcare spending remains resilient.

Global expansion and market positioning

Haleon maintains significant operations in the United States, a core market for consumer healthcare products, alongside established presence in Europe and emerging markets. The company's international footprint provides diversification across developed and growth markets, with particular strength in regions where OTC healthcare penetration continues to expand. US investors gain exposure to a company with substantial revenue generation from American consumers and healthcare distribution channels.

Read more

Additional news and developments on the stock can be explored via the linked overview pages.

More news on this stockInvestor relations

Conclusion

Haleon represents a focused consumer healthcare investment opportunity for US investors seeking exposure to the global OTC wellness market. The company's established brand portfolio, diversified geographic presence, and position within the FTSE 100 provide a stable foundation in the consumer health sector. As a pure-play consumer healthcare company, Haleon's performance reflects broader trends in self-care spending and preventive health management across developed markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | GB00BMX86B70 | HALEON | boerse | 69324531 | bgmi